NCT03937830 2026-06-05Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract CarcinomaNational Institutes of Health Clinical Center (CC)Phase 2 Active not recruiting27 enrolled